A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)Ravi Vij, Steven M. Devine, Kristina Laumann et al.|Transplantation and Cellular Therapy|2019Cited by 29